Table 2 Clinicopathologic features comparing ILC and non-ILC cohorts stratified by receptor subtype (ILC, invasive lobular carcinoma; IQR, interquartile range; HR, hormone receptor; HER2, human epidermal growth factor-2; TN, triple negative)
HR+HER2- ILC (n = 159) | HR+HER2-non-ILC (n = 1773) | p-value | TN or HER2+ILC (n = 57) | TN or HER2+ non-ILC (n = 3117) | p-value | ||
|---|---|---|---|---|---|---|---|
Median age, years (IQR) | 50 (46–59) | 49 (42–57) | <0.001 | 52 (46–61) | 49 (41–57) | 0.015 | |
Clinical T category | <0.001 | 0.161 | |||||
0 | 1 (0.6%) | 4 (0.2%) | 0 (0.0%) | 6 (0.2%) | |||
1 | 9 (5.7%) | 136 (7.7%) | 4 (7.0%) | 303 (9.7%) | |||
2 | 72 (45.3%) | 1110 (62.6%) | 30 (52.6%) | 1897 (60.9%) | |||
3 | 61 (38.4%) | 343 (19.3%) | 18 (31.2%) | 595 (19.1%) | |||
4 | 8 (5.0%) | 113 (6.4%) | 3 (5.2%) | 216 (6.9%) | |||
Missing | 8 (5.0%) | 67 (3.8%) | 2 (3.5%) | 100 (3.2%) | |||
Clinically node positive | 78 (49.1%) | 1023 (57.7%) | 0.037 | 29 (50.9%) | 1623 (52.1%) | 0.894 | |
Missing | 6 (3.8%) | 59 (3.3%) | 2 (3.5%) | 112 (3.6%) | |||
Histological grade | <0.001 | <0.001 | |||||
1 | 24 (15.1%) | 79 (4.5%) | 6 (10.5%) | 20 (0.6%) | |||
2 | 99 (62.3%) | 805 (45.4%) | 28 (49.1%) | 745 (23.9%) | |||
3 | 10 (6.3%) | 763 (43.0%) | 19 (33.3%) | 2130 (68.3%) | |||
Missing | 26 (16.4%) | 126 (7.1%) | 4 (7.0%) | 222 (7.1%) |
